<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?covid-19-tdm?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7779058</article-id>
    <article-id pub-id-type="pmid">33151287</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkaa997</article-id>
    <article-id pub-id-type="publisher-id">gkaa997</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>Narese/3</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>DrugCentral 2021 supports drug discovery and repositioning</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Avram</surname>
          <given-names>Sorin</given-names>
        </name>
        <aff><institution>Department of Computational Chemistry, “Coriolan Dragulescu’’ Institute of Chemistry</institution>, 24 Mihai Viteazu Blvd, Timişoara, Timiş, 300223, <country country="RO">România</country></aff>
        <xref ref-type="author-notes" rid="FN1"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Bologa</surname>
          <given-names>Cristian G</given-names>
        </name>
        <aff><institution>Translational Informatics Division, Department of Internal Medicine, University of New Mexico Health Sciences Center</institution>, Albuquerque, NM 87131, <country country="US">USA</country></aff>
        <aff><institution>UNM Comprehensive Cancer Center, University of New Mexico Health Sciences Center</institution>, Albuquerque, NM 87131, <country country="US">USA</country></aff>
        <xref ref-type="author-notes" rid="FN1"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Holmes</surname>
          <given-names>Jayme</given-names>
        </name>
        <aff><institution>Translational Informatics Division, Department of Internal Medicine, University of New Mexico Health Sciences Center</institution>, Albuquerque, NM 87131, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Bocci</surname>
          <given-names>Giovanni</given-names>
        </name>
        <aff><institution>Translational Informatics Division, Department of Internal Medicine, University of New Mexico Health Sciences Center</institution>, Albuquerque, NM 87131, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wilson</surname>
          <given-names>Thomas B</given-names>
        </name>
        <aff><institution>College of Pharmacy, University of New Mexico Health Sciences Center</institution>, Albuquerque, NM 87131, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2591-9948</contrib-id>
        <name>
          <surname>Nguyen</surname>
          <given-names>Dac-Trung</given-names>
        </name>
        <aff><institution>National Center for Advancing Translational Science</institution>, 9800 Medical Center Drive, Rockville, MD 20850, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Curpan</surname>
          <given-names>Ramona</given-names>
        </name>
        <aff><institution>Department of Computational Chemistry, “Coriolan Dragulescu’’ Institute of Chemistry</institution>, 24 Mihai Viteazu Blvd, Timişoara, Timiş, 300223, <country country="RO">România</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Halip</surname>
          <given-names>Liliana</given-names>
        </name>
        <aff><institution>Department of Computational Chemistry, “Coriolan Dragulescu’’ Institute of Chemistry</institution>, 24 Mihai Viteazu Blvd, Timişoara, Timiş, 300223, <country country="RO">România</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Bora</surname>
          <given-names>Alina</given-names>
        </name>
        <aff><institution>Department of Computational Chemistry, “Coriolan Dragulescu’’ Institute of Chemistry</institution>, 24 Mihai Viteazu Blvd, Timişoara, Timiş, 300223, <country country="RO">România</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yang</surname>
          <given-names>Jeremy J</given-names>
        </name>
        <aff><institution>Translational Informatics Division, Department of Internal Medicine, University of New Mexico Health Sciences Center</institution>, Albuquerque, NM 87131, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Knockel</surname>
          <given-names>Jeffrey</given-names>
        </name>
        <aff><institution>Department of Computer Science, University of New Mexico</institution>, Albuquerque, NM 87131, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Sirimulla</surname>
          <given-names>Suman</given-names>
        </name>
        <aff><institution>Department of Pharmaceutical Sciences, School of Pharmacy, The University of Texas at El Paso</institution>, TX 79902, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ursu</surname>
          <given-names>Oleg</given-names>
        </name>
        <aff><institution>Computational and Structural Chemistry, Merck &amp; Co., Inc.,</institution> 2000 Galloping Hill Road, Kenilworth, NJ 07033, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6195-6976</contrib-id>
        <name>
          <surname>Oprea</surname>
          <given-names>Tudor I</given-names>
        </name>
        <!--<email>toprea@salud.unm.edu</email>-->
        <aff><institution>Translational Informatics Division, Department of Internal Medicine, University of New Mexico Health Sciences Center</institution>, Albuquerque, NM 87131, <country country="US">USA</country></aff>
        <aff><institution>Computational and Structural Chemistry, Merck &amp; Co., Inc.,</institution> 2000 Galloping Hill Road, Kenilworth, NJ 07033, <country country="US">USA</country></aff>
        <aff><institution>Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg</institution>, 40530 Gothenburg, <country country="SE">Sweden</country></aff>
        <aff><institution>Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen</institution>, 2200 Copenhagen, <country country="DK">Denmark</country></aff>
        <xref ref-type="corresp" rid="COR1"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +1 505 925 7529; Fax: +1 505 925 7625; Email: <email>toprea@salud.unm.edu</email></corresp>
      <fn id="FN1">
        <p>The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <day>08</day>
      <month>1</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2020-11-05">
      <day>05</day>
      <month>11</month>
      <year>2020</year>
    </pub-date>
    <volume>49</volume>
    <issue>D1</issue>
    <fpage>D1160</fpage>
    <lpage>D1169</lpage>
    <history>
      <date date-type="accepted">
        <day>14</day>
        <month>10</month>
        <year>2020</year>
      </date>
      <date date-type="rev-recd">
        <day>09</day>
        <month>10</month>
        <year>2020</year>
      </date>
      <date date-type="received">
        <day>17</day>
        <month>9</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2021</copyright-year>
      <license license-type="cc-by" xlink:href="http://creativecommons.org/licenses/by/4.0/">
        <license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkaa997.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>DrugCentral is a public resource (<ext-link ext-link-type="uri" xlink:href="http://drugcentral.org">http://drugcentral.org</ext-link>) that serves the scientific community by providing up-to-date drug information, as described in previous papers. The current release includes 109 newly approved (October 2018 through March 2020) active pharmaceutical ingredients in the US, Europe, Japan and other countries; and two molecular entities (e.g. mefuparib) of interest for COVID19. New additions include a set of pharmacokinetic properties for ∼1000 drugs, and a sex-based separation of side effects, processed from FAERS (FDA Adverse Event Reporting System); as well as a drug repositioning prioritization scheme based on the market availability and intellectual property rights forFDA approved drugs. In the context of the COVID19 pandemic, we also incorporated REDIAL-2020, a machine learning platform that estimates anti-SARS-CoV-2 activities, as well as the ‘drugs in news’ feature offers a brief enumeration of the most interesting drugs at the present moment. The full database dump and data files are available for download from the DrugCentral web portal.</p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Institutes of Health</institution>
            <institution-id institution-id-type="DOI">10.13039/100000002</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>CA224370</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Cancer Institute</institution>
            <institution-id institution-id-type="DOI">10.13039/100000054</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>P30 CA118100</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>NIH NCATS Clinical and Translational Science Center for UNM</institution>
          </institution-wrap>
        </funding-source>
        <award-id>UL1 TR001449</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Intramural Research Program, Division of Preclinical Innovation, NIH NCATS</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Science Foundation</institution>
            <institution-id institution-id-type="DOI">10.13039/100000001</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>NSF-PREM</award-id>
        <award-id>DMR-1827745</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="10"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>INTRODUCTION</title>
    <p>DrugCentral integrates a broad spectrum of drug resources related to chemical structures, biological activities, regulatory data, pharmacology and drug formulations (<xref rid="B1" ref-type="bibr">1</xref>). Since 2018, DrugCentral has continuously strengthened its role as a key resource for the worldwide scientific community being additionally cross-referenced by several resources, such as UniProt (<xref rid="B2" ref-type="bibr">2</xref>), ChEBI (<xref rid="B3" ref-type="bibr">3</xref>), Hetionet (<xref rid="B4" ref-type="bibr">4</xref>), GUILDify (<xref rid="B5" ref-type="bibr">5</xref>), UniChem (<xref rid="B6" ref-type="bibr">6</xref>) and Guide to Pharmacology (<xref rid="B7" ref-type="bibr">7</xref>). DrugCentral served as primary resource for RepoDB, a drug repurposing database (<xref rid="B8" ref-type="bibr">8</xref>), a time-resolved computational drug repurposing algorithm (<xref rid="B9" ref-type="bibr">9</xref>), and an adverse drug event network for computational toxicology predictions (<xref rid="B10" ref-type="bibr">10</xref>). First introduced and published in the 2017 NAR database issue (<xref rid="B1" ref-type="bibr">1</xref>), DrugCentral reconciles the basic scientist's understanding of the ‘drug’ concept (active pharmaceutical ingredient) with the view of the patient and healthcare practitioner (pharmaceutical formulation). Since its initial launch, the two DrugCentral papers (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B11" ref-type="bibr">11</xref>) were cited more than 160 times cf. Google Scholar, and the website is accessed on average by ∼8000 visitors monthly, with a monthly average of ∼20 000 page views and over 20 000 full database downloads per year (as of 15 September 2020). Throughout regulatory and scientific documents, several terms are often used interchangeably: drug substance, new chemical (or molecular) entity and active (pharmaceutical) ingredient. While these terms have precise contextual meaning, in this paper preference is given to the term ‘drug’ as synonymous with these three concepts. The term ‘formulation’ is used when discussing pharmaceutical products.</p>
    <p>The current update adds newly approved drugs by the US Food and Drug Administration (FDA, <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/home">https://www.fda.gov/home</ext-link>) and the European Medicines Agency (EMA, <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en">https://www.ema.europa.eu/en</ext-link>) up to 31 March 2020. Drugs approved by Japan Pharmaceuticals and Medical Devices Agency (PMDA, <ext-link ext-link-type="uri" xlink:href="https://www.pmda.go.jp/english/index.html">https://www.pmda.go.jp/english/index.html</ext-link>) were also monitored up to the latest information available, i.e. November 2019. In addition, for numerous drugs present in DrugCentral since 2018, regulatory agency information was added according to their approval status.</p>
    <p>An important component of drug discovery and repositioning is information related to the pharmacokinetic (PK) properties of drugs, e.g. maximum recommended dose or half-life, as well as information related to side effects. In this regard, DrugCentral 2021 introduces critically reviewed information on PK, thus increasing the clinical pharmacology-related information coverage for drugs. Furthermore, adverse drug events separated by sex are tabulated at the drug level, to increase our understanding of drug safety.</p>
    <p>Sudden outbreaks can rapidly impact global health, as evidenced by the COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This pandemic has accelerated the need to rely on computational platforms (<xref rid="B12" ref-type="bibr">12</xref>) capable of identifying and advancing novel therapeutics for clinical evaluation. In this regard, the current DrugCentral update enables computational and medicinal chemists with (i) drug repositioning categories, i.e. an in-depth classification of drugs based on current market status and intellectual property rights in the US (<xref rid="B13" ref-type="bibr">13</xref>), to prioritize new therapeutic uses for ‘old drugs’; and (ii) a suite of machine learning models that predict anti-SARS-CoV-2 activities, REDIAL-2020 (<xref rid="B14" ref-type="bibr">14</xref>), to prioritize compounds against COVID-19.</p>
  </sec>
  <sec id="SEC2">
    <title>CURRENT CONTENT</title>
    <sec id="SEC2-1">
      <title>Active pharmaceutical ingredients</title>
      <p>The current DrugCentral update includes 109 newly approved drugs and two molecules (mefuparib and EIDD-2801, or ) with anti-SARS-CoV-2 potential to the 4531 indexed in 2018 (<xref rid="B11" ref-type="bibr">11</xref>). The vast majority of these were approved by the US FDA (95 drugs), followed by EMA (36 drugs), with 31 overlapping drugs. Compared to the additions in 2018, the number of newly approved drugs in Japan has nearly tripled, i.e. 16 new drugs compared to 6. In the past two years, the ratio of newly approved drugs between small organic molecules and biologics has changed in favor of the first class (70 small molecule drugs compared to 35 biologics), which contrasts with a more balanced ratio encountered in the last version of the database (<xref rid="B11" ref-type="bibr">11</xref>). Compared to the 2018 update, we note increases in the number of approved subtypes of biologics, such as antibody-drug conjugates (60% increase), oligonucleotides (50% increase) and monoclonal antibodies (30% increase). Approximately, half of the drugs processed (i.e. 52) are orphan drugs (<xref rid="B15" ref-type="bibr">15</xref>) pointing out the therapeutic gain in the group of rare diseases (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>). Out of the newly added drugs, the ChEMBL database (<xref rid="B17" ref-type="bibr">17</xref>) indexes 104 (91) of the 111 drugs, KEGG (<xref rid="B18" ref-type="bibr">18</xref>) indexes 107, DrugBank captures 105 and the Guide to Pharmacology 77 drugs, respectively (Table <xref rid="tbl1" ref-type="table">1</xref>).</p>
      <table-wrap id="tbl1" orientation="portrait" position="float">
        <label>Table 1.</label>
        <caption>
          <p>Differences in data content between DrugCentral 2016 (first release), 2018 and 2021 (current release)</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th colspan="4" align="center" rowspan="1">Entities (annotated drugs, or active pharmaceutical ingredients)</th>
            </tr>
            <tr>
              <th rowspan="1" colspan="1"/>
              <th rowspan="1" colspan="1">DrugCentral 2016</th>
              <th rowspan="1" colspan="1">DrugCentral 2018</th>
              <th rowspan="1" colspan="1">DrugCentral 2021</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">
                <italic>Active pharmaceutical ingredients</italic>
              </td>
              <td rowspan="1" colspan="1">4444</td>
              <td rowspan="1" colspan="1">4531</td>
              <td rowspan="1" colspan="1">4642</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> FDA drugs</td>
              <td rowspan="1" colspan="1">2021</td>
              <td rowspan="1" colspan="1">2094</td>
              <td rowspan="1" colspan="1">2220</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> EMA drugs</td>
              <td rowspan="1" colspan="1">239</td>
              <td rowspan="1" colspan="1">272</td>
              <td rowspan="1" colspan="1">354</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> PMDA drugs</td>
              <td rowspan="1" colspan="1">80</td>
              <td rowspan="1" colspan="1">86</td>
              <td rowspan="1" colspan="1">167</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> Small molecules</td>
              <td rowspan="1" colspan="1">3799</td>
              <td rowspan="1" colspan="1">3825</td>
              <td rowspan="1" colspan="1">3876</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> Biologics and peptides</td>
              <td rowspan="1" colspan="1">239</td>
              <td rowspan="1" colspan="1">282</td>
              <td rowspan="1" colspan="1">315</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> Other drugs</td>
              <td rowspan="1" colspan="1">294</td>
              <td rowspan="1" colspan="1">309</td>
              <td rowspan="1" colspan="1">395</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> Parent molecules</td>
              <td rowspan="1" colspan="1">199 (308)</td>
              <td rowspan="1" colspan="1">211 (327)</td>
              <td rowspan="1" colspan="1">216 (332)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic>Drug efficacy targets</italic>
              </td>
              <td rowspan="1" colspan="1">837 (1689)</td>
              <td rowspan="1" colspan="1">855 (1756)</td>
              <td rowspan="1" colspan="1">872 (1760)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> Human protein targets</td>
              <td rowspan="1" colspan="1">600 (1387)</td>
              <td rowspan="1" colspan="1">613 (1447)</td>
              <td rowspan="1" colspan="1">659 (1534)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> Infectious agents targets</td>
              <td rowspan="1" colspan="1">194 (221)</td>
              <td rowspan="1" colspan="1">197 (224)</td>
              <td rowspan="1" colspan="1">212 (230)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> Protein–drug crystal complex (PDB)</td>
              <td rowspan="1" colspan="1">48 (82)</td>
              <td rowspan="1" colspan="1">333 (139)</td>
              <td rowspan="1" colspan="1">411 (165)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> All protein–drug crystal complex (PDB)</td>
              <td rowspan="1" colspan="1">1452 (283)</td>
              <td rowspan="1" colspan="1">3991 (433)</td>
              <td rowspan="1" colspan="1">5576 (799)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> Bioactivity data points</td>
              <td rowspan="1" colspan="1">13 825 (1792)</td>
              <td rowspan="1" colspan="1">15 481 (1911)</td>
              <td rowspan="1" colspan="1">16 843 (2052)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> Human proteins</td>
              <td rowspan="1" colspan="1">10 427 (1605)</td>
              <td rowspan="1" colspan="1">11 241 (1692)</td>
              <td rowspan="1" colspan="1">12 373 (1837)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> Other species</td>
              <td rowspan="1" colspan="1">3398 (1002)</td>
              <td rowspan="1" colspan="1">4240 (1175)</td>
              <td rowspan="1" colspan="1">4470 (1235)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic>Pharmacological classification</italic>
              </td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> WHO ATC code</td>
              <td rowspan="1" colspan="1">4195 (2941)</td>
              <td rowspan="1" colspan="1">4889 (2978)</td>
              <td rowspan="1" colspan="1">5067 (3082)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> FDA Established Pharmacologic Class</td>
              <td rowspan="1" colspan="1">428 (1165)</td>
              <td rowspan="1" colspan="1">450 (1220)</td>
              <td rowspan="1" colspan="1">462 (1256)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> MeSH pharmacological action</td>
              <td rowspan="1" colspan="1">424 (2529)</td>
              <td rowspan="1" colspan="1">457 (2615)</td>
              <td rowspan="1" colspan="1">447 (2661)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> ChEBI ontology roles</td>
              <td rowspan="1" colspan="1">285 (1487)</td>
              <td rowspan="1" colspan="1">295 (1529)</td>
              <td rowspan="1" colspan="1">303 (1607)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic>Drug indications</italic>
              </td>
              <td rowspan="1" colspan="1">2224 (2247)</td>
              <td rowspan="1" colspan="1">2167 (2371)</td>
              <td rowspan="1" colspan="1">2241 (2496)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> Drug contra-indications</td>
              <td rowspan="1" colspan="1">1458 (1376)</td>
              <td rowspan="1" colspan="1">1407 (1379)</td>
              <td rowspan="1" colspan="1">1415 (1399)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> Drug off-label uses</td>
              <td rowspan="1" colspan="1">847 (646)</td>
              <td rowspan="1" colspan="1">817 (641)</td>
              <td rowspan="1" colspan="1">818 (654)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic>Pharmaceutical products</italic>
              </td>
              <td rowspan="1" colspan="1">67 064 (1660)</td>
              <td rowspan="1" colspan="1">77 484 (1716)</td>
              <td rowspan="1" colspan="1">108 035 (1810)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> Rx pharmaceutical products</td>
              <td rowspan="1" colspan="1">29 665 (1561)</td>
              <td rowspan="1" colspan="1">34 192 (1609)</td>
              <td rowspan="1" colspan="1">56 515 (1697)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> OTC pharmaceutical products</td>
              <td rowspan="1" colspan="1">37 399 (286)</td>
              <td rowspan="1" colspan="1">43 292 (296)</td>
              <td rowspan="1" colspan="1">51 520 (319)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic>External identifiers</italic>
              </td>
              <td rowspan="1" colspan="1">61 349 (4444)</td>
              <td rowspan="1" colspan="1">69 516 (4531)</td>
              <td rowspan="1" colspan="1">63 658 (4639)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> CAS registry number</td>
              <td rowspan="1" colspan="1">6072 (4444)</td>
              <td rowspan="1" colspan="1">6200 (4531)</td>
              <td rowspan="1" colspan="1">6350 (4642)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> PubChem Compound Id</td>
              <td rowspan="1" colspan="1">4175 (4175)</td>
              <td rowspan="1" colspan="1">4289 (4308)</td>
              <td rowspan="1" colspan="1">4399 (4412)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> FDA Unique Ingredient Identifier (UNII)</td>
              <td rowspan="1" colspan="1">4304 (4304)</td>
              <td rowspan="1" colspan="1">4391 (4391)</td>
              <td rowspan="1" colspan="1">4505 (4505)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> ChEMBL-db id</td>
              <td rowspan="1" colspan="1">5615 (4075)</td>
              <td rowspan="1" colspan="1">6077 (4330)</td>
              <td rowspan="1" colspan="1">6473 (4469)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> WHO INN id</td>
              <td rowspan="1" colspan="1">3519 (3519)</td>
              <td rowspan="1" colspan="1">3589 (3589)</td>
              <td rowspan="1" colspan="1">3700 (3700)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> SNOMED-CT</td>
              <td rowspan="1" colspan="1">4745 (2637)</td>
              <td rowspan="1" colspan="1">4968 (2815)</td>
              <td rowspan="1" colspan="1">5193 (2910)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> KEGG DRUG</td>
              <td rowspan="1" colspan="1">3501 (3501)</td>
              <td rowspan="1" colspan="1">3576 (3576)</td>
              <td rowspan="1" colspan="1">3697 (3698)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> NDFRT</td>
              <td rowspan="1" colspan="1">4171 (2406)</td>
              <td rowspan="1" colspan="1">4256 (2479)</td>
              <td rowspan="1" colspan="1">3464 (3314)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> RxNorm RxCUI</td>
              <td rowspan="1" colspan="1">2897 (2897)</td>
              <td rowspan="1" colspan="1">2988 (2991)</td>
              <td rowspan="1" colspan="1">3107 (3110)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> IUPHAR/BPS ligand id</td>
              <td rowspan="1" colspan="1">1345 (1345)</td>
              <td rowspan="1" colspan="1">1391 (1395)</td>
              <td rowspan="1" colspan="1">1599 (1599)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> UMLS CUI</td>
              <td rowspan="1" colspan="1">2839 (2839)</td>
              <td rowspan="1" colspan="1">2835 (2835)</td>
              <td rowspan="1" colspan="1">2835 (2835)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> CHEBI</td>
              <td rowspan="1" colspan="1">2557 (2557)</td>
              <td rowspan="1" colspan="1">3824 (3830)</td>
              <td rowspan="1" colspan="1">3855 (3861)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> MeSH</td>
              <td rowspan="1" colspan="1">4063 (3846)</td>
              <td rowspan="1" colspan="1">4180 (3946)</td>
              <td rowspan="1" colspan="1">4299 (4056)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> DrugBank</td>
              <td rowspan="1" colspan="1">2473 (2388)</td>
              <td rowspan="1" colspan="1">2773 (2858)</td>
              <td rowspan="1" colspan="1">3685 (3699)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> Protein Databank ligand id</td>
              <td rowspan="1" colspan="1">646 (618)</td>
              <td rowspan="1" colspan="1">713 (695)</td>
              <td rowspan="1" colspan="1">695 (659)</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="SEC2-2">
      <title>Bioactivity data and mechanism of action</title>
      <p>The present release adds 1379 new bioactivity datapoints from ChEMBL (<xref rid="B17" ref-type="bibr">17</xref>) and the Guide to Pharmacology (<xref rid="B7" ref-type="bibr">7</xref>) using automated pipelines, 79% and 8%, respectively; and manually curated scientific literature and approved drug label data (13%). Newly introduced drugs are associated with 551 bioactivity points from ChEMBL (65.5%), manual curation from literature (24.14%), the Guide to Pharmacology (6.17%) and approved drug labels (4.17%), respectively; as well as 109 mechanism of action (MoA or <bold>Tclin</bold> proteins—<italic>vide infra</italic>) targets, with kinases (26%) and enzymes (21%) representing the major target categories, followed by G-protein-coupled receptors—GPCRs (17%) and tumor-associated antigens (9%). Since 2018, 46 novel MoA targets, associated with 32 newly approved drugs, have been introduced (Table <xref rid="tbl2" ref-type="table">2</xref>).</p>
      <table-wrap id="tbl2" orientation="portrait" position="float">
        <label>Table 2.</label>
        <caption>
          <p>New active pharmaceutical ingredients with novel mechanisms of action approved since the 2018 release of DrugCentral</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Active Ingredient(s)</th>
              <th rowspan="1" colspan="1">Target</th>
              <th rowspan="1" colspan="1">Target Class<sup>a</sup></th>
              <th rowspan="1" colspan="1">Agency</th>
              <th rowspan="1" colspan="1">Indication</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">crizanlizumab</td>
              <td rowspan="1" colspan="1">SELP</td>
              <td rowspan="1" colspan="1">Adhesion</td>
              <td rowspan="1" colspan="1">FDA</td>
              <td rowspan="1" colspan="1">Vaso-occlusive crisis in sickle cell disease</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">luspatercept</td>
              <td rowspan="1" colspan="1">GDF11, MSTN</td>
              <td rowspan="1" colspan="1">Cytokine</td>
              <td rowspan="1" colspan="1">FDA</td>
              <td rowspan="1" colspan="1">Beta thalassemia</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">emapalumab</td>
              <td rowspan="1" colspan="1">IFNG</td>
              <td rowspan="1" colspan="1">Cytokine</td>
              <td rowspan="1" colspan="1">FDA</td>
              <td rowspan="1" colspan="1">Primary hemophagocytic lymphohistiocytosis</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">prabotulinumtoxinA</td>
              <td rowspan="1" colspan="1">SNAP25</td>
              <td rowspan="1" colspan="1">Cytosolic other</td>
              <td rowspan="1" colspan="1">FDA</td>
              <td rowspan="1" colspan="1">Rhytidectomy of glabellar frown lines</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">botulinum toxin type A</td>
              <td rowspan="1" colspan="1">SNAP25</td>
              <td rowspan="1" colspan="1">Cytosolic other</td>
              <td rowspan="1" colspan="1">EMA</td>
              <td rowspan="1" colspan="1">Rhytidectomy of glabellar frown lines</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">andexanet alfa</td>
              <td rowspan="1" colspan="1">rivaroxaban, apixaban</td>
              <td rowspan="1" colspan="1">Drug</td>
              <td rowspan="1" colspan="1">FDA, EMA</td>
              <td rowspan="1" colspan="1">Direct-acting anticoagulant adverse reaction</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">roxadustat</td>
              <td rowspan="1" colspan="1">EGLN1, EGLN2, EGLN3</td>
              <td rowspan="1" colspan="1">Enzyme</td>
              <td rowspan="1" colspan="1">PMDA</td>
              <td rowspan="1" colspan="1">Anemia in chronic kidney disease, refractory anemia</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ivosidenib</td>
              <td rowspan="1" colspan="1">IDH1</td>
              <td rowspan="1" colspan="1">Enzyme</td>
              <td rowspan="1" colspan="1">FDA</td>
              <td rowspan="1" colspan="1">Acute myeloid leukemia</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">romosozumab</td>
              <td rowspan="1" colspan="1">SOST</td>
              <td rowspan="1" colspan="1">Glycoprotein</td>
              <td rowspan="1" colspan="1">FDA</td>
              <td rowspan="1" colspan="1">Postmenopausal osteoporosis</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">fremanezumab</td>
              <td rowspan="1" colspan="1">CALCA</td>
              <td rowspan="1" colspan="1">GPCR</td>
              <td rowspan="1" colspan="1">FDA, EMA</td>
              <td rowspan="1" colspan="1">Migraine</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">galcanezumab</td>
              <td rowspan="1" colspan="1">CALCA</td>
              <td rowspan="1" colspan="1">GPCR</td>
              <td rowspan="1" colspan="1">FDA</td>
              <td rowspan="1" colspan="1">Migraine</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">erenumab</td>
              <td rowspan="1" colspan="1">CALCRL</td>
              <td rowspan="1" colspan="1">GPCR</td>
              <td rowspan="1" colspan="1">FDA, EMA</td>
              <td rowspan="1" colspan="1">Migraine</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ubrogepant</td>
              <td rowspan="1" colspan="1">CALCRL</td>
              <td rowspan="1" colspan="1">GPCR</td>
              <td rowspan="1" colspan="1">FDA</td>
              <td rowspan="1" colspan="1">Migraine</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">lasmiditan</td>
              <td rowspan="1" colspan="1">HTR1F</td>
              <td rowspan="1" colspan="1">GPCR</td>
              <td rowspan="1" colspan="1">FDA</td>
              <td rowspan="1" colspan="1">Migraine</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">cannabidiol</td>
              <td rowspan="1" colspan="1">GPR55</td>
              <td rowspan="1" colspan="1">GPCR</td>
              <td rowspan="1" colspan="1">FDA, EMA</td>
              <td rowspan="1" colspan="1">Lennox-Gastaut syndrome, severe myoclonic epilepsy in infancy</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">bremelanotide</td>
              <td rowspan="1" colspan="1">MC4R</td>
              <td rowspan="1" colspan="1">GPCR</td>
              <td rowspan="1" colspan="1">FDA</td>
              <td rowspan="1" colspan="1">Lack or loss of sexual desire</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">larotrectinib</td>
              <td rowspan="1" colspan="1">NTRK2, NTRK3</td>
              <td rowspan="1" colspan="1">Kinase</td>
              <td rowspan="1" colspan="1">FDA, EMA</td>
              <td rowspan="1" colspan="1">Malignant neoplasm</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">entrectinib</td>
              <td rowspan="1" colspan="1">NTRK2, NTRK3, ROS1</td>
              <td rowspan="1" colspan="1">Kinase</td>
              <td rowspan="1" colspan="1">FDA, PMDA</td>
              <td rowspan="1" colspan="1">Reactive oxygen species 1 positive non-small cell lung cancer, solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">duvelisib</td>
              <td rowspan="1" colspan="1">PIK3CG</td>
              <td rowspan="1" colspan="1">Kinase</td>
              <td rowspan="1" colspan="1">FDA</td>
              <td rowspan="1" colspan="1">Chronic lymphoid leukemia, malignant lymphoma - small lymphocytic, follicular non-Hodgkin's lymphoma</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">lorlatinib</td>
              <td rowspan="1" colspan="1">ROS1, LTK, FER, FES, NTRK2, NTRK3, PTK2, PTK2B, TNK2</td>
              <td rowspan="1" colspan="1">Kinase</td>
              <td rowspan="1" colspan="1">FDA, EMA, PMDA</td>
              <td rowspan="1" colspan="1">Non-small cell lung cancer lung cancer</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">fostamatinib</td>
              <td rowspan="1" colspan="1">SYK</td>
              <td rowspan="1" colspan="1">Kinase</td>
              <td rowspan="1" colspan="1">FDA, EMA</td>
              <td rowspan="1" colspan="1">Immune thrombocytopenia</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ibalizumab</td>
              <td rowspan="1" colspan="1">CD4</td>
              <td rowspan="1" colspan="1">Membrane receptor</td>
              <td rowspan="1" colspan="1">FDA, EMA</td>
              <td rowspan="1" colspan="1">Human immunodeficiency virus infection</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">tagraxofusp</td>
              <td rowspan="1" colspan="1">IL3RA</td>
              <td rowspan="1" colspan="1">Membrane receptor</td>
              <td rowspan="1" colspan="1">FDA</td>
              <td rowspan="1" colspan="1">Blastic plasmacytoid dendritic cell neoplasm</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">selinexor</td>
              <td rowspan="1" colspan="1">XPO1</td>
              <td rowspan="1" colspan="1">Nuclear other</td>
              <td rowspan="1" colspan="1">FDA</td>
              <td rowspan="1" colspan="1">Relapse multiple myeloma</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">givosiran</td>
              <td rowspan="1" colspan="1">ALAS1</td>
              <td rowspan="1" colspan="1">RNA</td>
              <td rowspan="1" colspan="1">FDA, EMA</td>
              <td rowspan="1" colspan="1">Hepatic porphyria</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">volanesorsen</td>
              <td rowspan="1" colspan="1">APOC3</td>
              <td rowspan="1" colspan="1">RNA</td>
              <td rowspan="1" colspan="1">EMA</td>
              <td rowspan="1" colspan="1">Chylomicronemia syndrome</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">golodirsen</td>
              <td rowspan="1" colspan="1">DMD</td>
              <td rowspan="1" colspan="1">RNA</td>
              <td rowspan="1" colspan="1">FDA</td>
              <td rowspan="1" colspan="1">Duchenne muscular dystrophy</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">burosumab</td>
              <td rowspan="1" colspan="1">FGF23</td>
              <td rowspan="1" colspan="1">Secreted</td>
              <td rowspan="1" colspan="1">FDA, EMA, PMDA</td>
              <td rowspan="1" colspan="1">Familial x-linked hypophosphatemic vitamin D refractory rickets</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">voxelotor</td>
              <td rowspan="1" colspan="1">HBA1</td>
              <td rowspan="1" colspan="1">Transporter</td>
              <td rowspan="1" colspan="1">FDA</td>
              <td rowspan="1" colspan="1">Sickle cell disease</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">sotagliflozin</td>
              <td rowspan="1" colspan="1">SLC5A1</td>
              <td rowspan="1" colspan="1">Transporter</td>
              <td rowspan="1" colspan="1">EMA</td>
              <td rowspan="1" colspan="1">Diabetes mellitus type 1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">tenapanor</td>
              <td rowspan="1" colspan="1">SLC9A3</td>
              <td rowspan="1" colspan="1">Transporter</td>
              <td rowspan="1" colspan="1">FDA</td>
              <td rowspan="1" colspan="1">Irritable bowel syndrome characterized by constipation</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">polatuzumab vedotin</td>
              <td rowspan="1" colspan="1">CD79B</td>
              <td rowspan="1" colspan="1">Tumor-associated antigen</td>
              <td rowspan="1" colspan="1">FDA, EMA</td>
              <td rowspan="1" colspan="1">Diffuse large B-cell lymphoma refractory</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">enfortumab vedotin</td>
              <td rowspan="1" colspan="1">NECTIN4</td>
              <td rowspan="1" colspan="1">Tumor-associated antigen</td>
              <td rowspan="1" colspan="1">FDA</td>
              <td rowspan="1" colspan="1">Metastatic urothelial carcinoma</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">caplacizumab</td>
              <td rowspan="1" colspan="1">VWF</td>
              <td rowspan="1" colspan="1">Unclassified</td>
              <td rowspan="1" colspan="1">EMA, FDA</td>
              <td rowspan="1" colspan="1">Thrombotic thrombocytopenic purpura</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="T2TFN1">
            <p><sup>a</sup>SELP, P-selectin; GDF11, Growth/differentiation factor 11; MSTN, Growth/differentiation factor 8; IFNG, Interferon gamma; SNAP25, Synaptosomal-associated protein 25; EGLN1, Egl nine homolog 1; EGLN2, Egl nine homolog 2; EGLN3, Egl nine homolog 3; IDH1, Isocitrate dehydrogenase [NADP] cytoplasmic; SOST, Sclerostin; CALCA, Calcitonin gene-related peptide 1; CALCRL, Calcitonin-gene-related peptide receptor; HTR1F, 5-hydroxytryptamine receptor 1F; GPR55, G-protein coupled receptor 55; MC4R, Melanocortin receptor 4; NTRK2, BDNF/NT-3 growth factors receptor; NTRK3, NT-3 growth factor receptor; ROS1, Proto-oncogene tyrosine-protein kinase ROS; PIK3CG, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform; LTK, Leukocyte tyrosine kinase receptor; FER, Tyrosine-protein kinase Fer; FES, Tyrosine-protein kinase Fes/Fps; PTK2, Focal adhesion kinase 1; PTK2B, Protein-tyrosine kinase 2-beta;TNK2,Activated CDC42 kinase 1; SYK, Tyrosine-protein kinase SYK; CD4,T-cell surface glycoprotein CD4; IL3RA, Interleukin-3 receptor; XPO1,Exportin-1; ALAS1, aminolevulinate synthase1 (ALAS1) mRNA; APOC3, apolipoprotein C-III (apoC-III) mRNA; DMD, exon 53 of dystrophin pre-mRNA; FGF23, Fibroblast growth factor 23; HBA1, hemoglobin subunit alpha; SLC5A1, Sodium/glucose cotransporter 1; SLC9A3, Sodium/hydrogen exchanger 3; CD79B, B-cell antigen receptor complex-associated protein beta chain; NECTIN4, Nectin-4; VWF, von Willebrand factor;</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Our knowledge-based protein classification (<xref rid="B19" ref-type="bibr">19</xref>) bins human proteins into four categories, according to their ‘target development level’ (TDL): <bold>Tclin</bold> are MoA-designated drug targets via which approved drugs act (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref>), currently 659 human proteins; <bold>Tchem</bold> are proteins that are not <bold>Tclin</bold>, but are known to bind small molecules with high potency; <bold>Tbio</bold> includes proteins that have Gene Ontology (<xref rid="B22" ref-type="bibr">22</xref>) ‘leaf’ (lowest level) term annotations based on experimental evidence; or meet two of the following three conditions: A fractional publication count (<xref rid="B23" ref-type="bibr">23</xref>) above five, three or more Gene RIF, ‘Reference Into Function’ annotations (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/gene/about-generif">https://www.ncbi.nlm.nih.gov/gene/about-generif</ext-link>), or 50 or more commercial antibodies, as counted in the Antibodypedia portal (<xref rid="B24" ref-type="bibr">24</xref>). The fourth category, <bold>Tdark</bold>, currently includes ∼31% of the human proteome that were manually curated at the primary sequence level in UniProt, but do not meet any of the <bold>Tclin</bold>, <bold>Tchem</bold> or <bold>Tbio</bold> criteria. DrugCentral 2021 contains 669 <bold>Tchem</bold>, 219 <bold>Tbio</bold> and 14 <bold>Tdark</bold> proteins linked to 3859, 607 and 39 bioactivity points, respectively. These proteins are mapped onto the Target Central Resource Database (TCRD) and interfaced with the TCRD portal, Pharos, respectively (<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref>).</p>
    </sec>
    <sec id="SEC2-3">
      <title>Pharmacological classification</title>
      <p>New and existing drugs in DrugCentral were mapped (or remapped) into the latest versions of the World Health Organization Anatomic, Therapeutic and Chemical classification system (WHO ATC, <ext-link ext-link-type="uri" xlink:href="https://www.whocc.no/">https://www.whocc.no/</ext-link>), the FDA Established Pharmacologic Class (EPC, <ext-link ext-link-type="uri" xlink:href="https://bit.ly/2OWiJdH">https://bit.ly/2OWiJdH</ext-link>), the Medical Subject Headings (MeSH) (<xref rid="B27" ref-type="bibr">27</xref>) and ChEBI (<xref rid="B3" ref-type="bibr">3</xref>) pharmacological classifications using the adaptive mapping schemes described in 2018. The resulting pharmacological additions are described in Table <xref rid="tbl1" ref-type="table">1</xref>. Among novel drugs, 78 were linked to 136 pharmacologic classifications; 313 of the drugs were mapped to 424 additional pharmacologic terms.</p>
    </sec>
    <sec id="SEC2-4">
      <title>Pharmaceutical formulations</title>
      <p>FDA pharmaceutical formulations were assessed using DailyMed (<ext-link ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/">https://dailymed.nlm.nih.gov/</ext-link>) data, downloaded on 9 May 2020. A total of 31 731 new formulations with effective dates starting from 30 June 2018 were added to DrugCentral 2021. The vast majority of these products (82%) are for oral (17 052) and topical (9832) administrations. The percentage of human prescription (Rx) products (52.7%) remains only slightly higher compared to OTCs.</p>
    </sec>
  </sec>
  <sec id="SEC3">
    <title>NEW DATA AND FUNCTIONALITY</title>
    <sec id="SEC3-1">
      <title>Drug repurposing categories</title>
      <p>The current version of DrugCentral includes a recently published drug repurposing categorization scheme (<xref rid="B13" ref-type="bibr">13</xref>), according to which drugs are sorted based on their market availability and intellectual property rights (including exclusivity protections) into three distinct categories: OFP, or off-patent, which are on-market drugs with expired patents or exclusivities; ONP, or on-patent, which are on-market drugs covered by current patents and exclusivity protections; and OFM, or off-market, which includes all previously marketed drugs that have been discontinued or withdrawn, respectively. The analysis, based on the US FDA’s Orange Book (FDA-OB), mapped small organic molecules and peptides from DrugCentral (having molecular weight between 100 and 1250) onto FDA-OB. In total, 996 drugs were categorized as OFP, 320 as OFM and 237 as ONP (Figure <xref ref-type="fig" rid="F1">1</xref>), respectively. These drugs can be found in a variety of pharmaceutical formulations, but oral drugs appear to be predominant in all three sets: 73% in OFP, 82% in ONP and 62% in OFM. Moreover, the data shows an increasing proportion of oral drugs in more recently approved drugs (i.e. ONP and OFP compared to OFM).</p>
      <fig id="F1" orientation="portrait" position="float">
        <label>Figure 1.</label>
        <caption>
          <p>Bar plot showing the number of DrugCentral active pharmaceutical ingredients—drugs (formulated for oral versus non-oral route administration) mapped to FDA-OB and labeled as: OFP (on-market but off-patent), OFM (off-market) and ONP (on-market, on-patent), respectively (<xref rid="B13" ref-type="bibr">13</xref>).</p>
        </caption>
        <graphic xlink:href="gkaa997fig1"/>
      </fig>
      <p>This classification scheme allows researchers to inform their decisions with respect to drug repositioning based on the existing intellectual property landscape. Given that, in time, novel drugs will be added and other drugs will change categories (i.e. ONP drugs naturally migrate to OFP and, possibly, to OFM), this drug repositioning classification will be updated on a yearly basis following the previously described workflow (<xref rid="B13" ref-type="bibr">13</xref>). This feature complements the pharmacopedic nature of DrugCentral, providing the scientific community (academia and industry) support to more efficiently advance ‘old’ drugs toward new therapeutic opportunities (<xref rid="B28" ref-type="bibr">28</xref>).</p>
    </sec>
    <sec id="SEC3-2">
      <title>ADMET-PK data</title>
      <p>DrugCentral 2021 now includes nine measured properties that describe pharmacokinetics (PK) such as absorption, distribution, metabolism, excretion and toxicity (ADMET) for a number of drugs. These ADMET-PK data were retrieved from five authoritative references (<xref rid="B29" ref-type="bibr">29–33</xref>), which themselves are extensively curated compilations from biomedical literature or drug records. These ADMET-PK properties are highly relevant for understanding the fate of drugs in the human body, for estimating dosage regimens and for conducting data analyses or machine learning studies. The number of drugs indexed with each property is summarized in Figure <xref ref-type="fig" rid="F2">2</xref>. What follows is a brief description of the ADMET-PK properties incorporated in DrugCentral 2021.</p>
      <list list-type="roman-lower">
        <list-item>
          <p>The absolute oral bioavailability (BA) indicates the fraction of the orally dosed drug that is absorbed through the gut, undergoes first-pass metabolism (gut and liver) and reaches systemic circulation.</p>
        </list-item>
        <list-item>
          <p>The volume of distribution at steady state (Vd) is the theoretical volume (expressed in L/kg) necessary to contain the measured steady-state drug concentration in plasma.</p>
        </list-item>
        <list-item>
          <p>The systemic (or total) clearance (CL) is the volume of plasma from which a drug is completely removed from the body. It is expressed as mL/min/kg and it is the sum of the clearance of the drug by each organ: kidneys, liver, etc.</p>
        </list-item>
        <list-item>
          <p>Half-life (t1/2) is the time (expressed in hours) it takes for a drug to decrease to half of its maximum concentration in plasma.</p>
        </list-item>
        <list-item>
          <p>The fraction unbound (fu) is the fraction of drug that is not bound to plasma proteins.</p>
        </list-item>
        <list-item>
          <p>Water solubility (S) indicates the degree of a drug dissolving in water at neutral pH and 37°C.</p>
        </list-item>
        <list-item>
          <p>The extent of metabolism (EoM) is the fraction of the drug (API) excreted unchanged (mainly, in urine).</p>
        </list-item>
        <list-item>
          <p>The Biopharmaceutical Drug Disposition Classification System (BDDCS) is an adaptation of the FDA Biopharmaceutical Classification System for bioequivalence studies. In BDDCS, drugs are assigned to four categories in accordance with solubility and EoM cutoffs: Class 1 are high solubility, extensively metabolized drugs; Class 2 are low solubility, extensively metabolized drugs; Class 3 are high solubility, poorly metabolized drugs; and Class 4 are low solubility, poorly metabolized drugs, respectively. It should be noted that the solubility used for BDDCS is the one defined by FDA guidance: the solubility of the formulated active ingredient at its highest approved dose strength, in 250 mL of water, at 37°C, over the pH range 1–6.8 <underline>(</underline><ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/media/70963/download">https://www.fda.gov/media/70963/download</ext-link><underline>)</underline>. BDDCS has proven to be useful in understanding the role of drug transporters (<xref rid="B34" ref-type="bibr">34</xref>), in predicting the brain permeability of drugs (<xref rid="B35" ref-type="bibr">35</xref>) and in understanding the PK specificity of drug targets (<xref rid="B36" ref-type="bibr">36</xref>). BDDCS, S and EoM data gathered from two separate publications (<xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B32" ref-type="bibr">32</xref>).</p>
        </list-item>
        <list-item>
          <p>The Maximum Recommended Therapeutic Daily Dose (MRTD) is the dose threshold above which a drug starts to manifest adverse reactions. Therefore, it is a measure of the toxicity potential of a drug. While the original publication (<xref rid="B33" ref-type="bibr">33</xref>) reported MRTD in mg/kg/day units, whereas DrugCentral 2021 uses μM/kg/day (i.e. the mg quantities were divided by the molecular weight of the specific active ingredient). MRTD values were re-normalized to an average body weight of 70 kg instead of the original 60 kg, although the ‘average 70 kg man’ concept needs re-evaluation (<xref rid="B37" ref-type="bibr">37</xref>).</p>
        </list-item>
      </list>
      <fig id="F2" orientation="portrait" position="float">
        <label>Figure 2.</label>
        <caption>
          <p>Bar plot showing the number of drugs indexed from literature sources for each ADMET-PK (absorption, distribution, metabolism, excretion and toxicity—pharmacokinetics) property. Colors indicate the different literature sources: orange for BA—bioavailability (<xref rid="B29" ref-type="bibr">29</xref>); blue for Vd—Volume of distribution, CL—Clearance, t1/2—half-life time and fu—fraction unbound (<xref rid="B30" ref-type="bibr">30</xref>); purple for S—water solubility, EoM—Extent of Metabolism and BDDCS—Biopharmaceutical Drug Disposition Classification System (<xref rid="B31" ref-type="bibr">31</xref>), (<xref rid="B32" ref-type="bibr">32</xref>); and green for MRTD—Maximum Recommended Therapeutic Daily Dose (<xref rid="B33" ref-type="bibr">33</xref>), respectively.</p>
        </caption>
        <graphic xlink:href="gkaa997fig2"/>
      </fig>
      <p>As new data points become available, these will be added in DrugCentral.</p>
    </sec>
    <sec id="SEC3-3">
      <title>Sex-differences in adverse drug events</title>
      <p>FAERS (FDA Adverse Event Reporting System, <ext-link ext-link-type="uri" xlink:href="https://open.fda.gov/data/faers/">https://open.fda.gov/data/faers/</ext-link>) data were first incorporated in DrugCentral 2018 (<xref rid="B11" ref-type="bibr">11</xref>). Compared to the 2018 release, there was a 10% increase in unique drugs (from 2023 to 2220), which are associated with 12,098 unique MedDRA terms (i.e. adverse events—AEs; Medical Dictionary for Regulatory Activities, <ext-link ext-link-type="uri" xlink:href="https://www.meddra.org/">https://www.meddra.org/</ext-link>), resulting in 739 990 drug-AE combinations. The larger the log likelihood ratio LLR value (<xref rid="B38" ref-type="bibr">38</xref>) for an AE, the more likely the event occurred due to a drug, and significant signals can be encountered for AEs with LLRs larger than the calculated drug-specific threshold values (<italic>t</italic>). Statistically relevant signals for the LLR test yield 1618 unique drugs associated with 8185 unique AEs, for a total of 147 191 (20%) significant drug-AE combinations. The DrugCentral 2021 FAERS dataset supports sex-specific granularity for AEs. An overview of the sex differences described in Table <xref rid="tbl3" ref-type="table">3</xref> shows a larger number of AEs reported for women compared to men. Indeed, at LLR &gt; 5*<italic>t</italic>, the number of API-AE pairs almost doubles in females. This phenomenon, first reported in the US using FAERS data (<xref rid="B39" ref-type="bibr">39</xref>), and independently confirmed in the Netherlands (<xref rid="B40" ref-type="bibr">40</xref>), shows that sex bias in medical treatment persists, ten years after it was first discussed (<xref rid="B41" ref-type="bibr">41</xref>). Creating an interface that highlights sex-differences in AEs may facilitate further analyses and may reveal essential drug actions to pave the way for truly personalized medicine (<xref rid="B42" ref-type="bibr">42</xref>).</p>
      <table-wrap id="tbl3" orientation="portrait" position="float">
        <label>Table 3.</label>
        <caption>
          <p>Summary of sex-specific adverse event data from FAERS, at different LLR levels</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Categories</th>
              <th colspan="2" align="center" rowspan="1">Number of API-AE pairs (unique drugs/unique AEs)</th>
            </tr>
            <tr>
              <th rowspan="1" colspan="1"/>
              <th rowspan="1" colspan="1">MALE</th>
              <th rowspan="1" colspan="1">FEMALE</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">LLR &gt; 0</td>
              <td rowspan="1" colspan="1">403 993 (1824/9160)</td>
              <td rowspan="1" colspan="1">467 048 (1.936 /9872)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">LLR &gt; 2*<italic>t</italic></td>
              <td rowspan="1" colspan="1">31 740 (968/3316)</td>
              <td rowspan="1" colspan="1">50 282 (1124/4163)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">LLR &gt; 5*<italic>t</italic></td>
              <td rowspan="1" colspan="1">12 014 (737/1735)</td>
              <td rowspan="1" colspan="1">20 845 (866/2397)</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="T3TFN1">
            <p>AE: adverse event; LLR: log likelihood ratio; t, LLR threshold.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="SEC3-4">
      <title>REDIAL-2020</title>
      <p>DrugCentral 2021 incorporates a web server named ‘REDIAL-2020’ to efficiently estimate anti-SARS-CoV-2 activities from molecular structure (<xref rid="B14" ref-type="bibr">14</xref>). REDIAL-2020 hosts a suite of machine learning (ML) models that represent various experimental assays related to live virus infectivity (LVI), viral entry (VE) and virus replication (VR) process. It currently consists of six ML models that represent six assays using data from the NCATS (National Center for Advancing Translational Sciences) COVID19 portal (<xref rid="B43" ref-type="bibr">43</xref>). These assays are: the SARS-CoV-2 cytopathic effect, CPE (LVI) (<xref rid="B44" ref-type="bibr">44</xref>); Vero E6 host cell cytotoxicity (LVI counterscreen); Spike-ACE2 protein-protein interaction (AlphaLISA; VE) (<xref rid="B45" ref-type="bibr">45</xref>), TruHit (VE) counterscreen; angiotensin-converting enzyme 2 (ACE2; VE) inhibition; and 3C-like proteinase (3CL or Mpro; VR) inhibition (<xref rid="B46" ref-type="bibr">46</xref>). These models use chemical structures (or drug names; or PubChem CIDs) as input; a similarity search retrieves similar compounds in the NCATS dataset, and sorts them according to the Tanimoto similarity score. In addition to anti-SARS-CoV-2 activities, the top 10 most similar entries compared to the query molecule are displayed. Promising compounds are the ones that are (i) active in the CPE but inactive in cytotoxicity LVI models; (ii) active in the Spike-ACE2 (AlphaLISA) model and inactive in both the TruHit and ACE2 counterscreen VE models; or (iii) active in 3CL (VR) model; or any combination of the above. We are committed to update the current models periodically and build additional models to represent more assays as new data gets available in the literature.</p>
      <p>Initially for each assay type, ML models based on each descriptor category (fingerprint, pharmacophore and physicochemical) were developed by employing 22 different ML algorithms from <italic>scikit-learn</italic> (<xref rid="B47" ref-type="bibr">47</xref>). The best performing model from each descriptor type was used to build consensus models. Finally, the best performing models according to their performance on the validation and test sets (15% of the initial set, each) were picked and implemented in the REDIAL-2020 prediction server. Against three different external sets, these models exhibited predictivity in the range of 60–75%. An in-depth discussion of the models, their training procedures, performance, external predictivity and implementation are discussed elsewhere (<xref rid="B14" ref-type="bibr">14</xref>). Based on the same concept as the L1000 gene perturbation profile similarity, which was implemented in DrugCentral 2018 (<xref rid="B11" ref-type="bibr">11</xref>), REDIAL-2020 serves a complementary need, i.e. the search for drugs effective against COVID-19, as opposed to the evidence-based (factual) DrugCentral system. Both aim to support the process of drug discovery and repositioning.</p>
    </sec>
    <sec id="SEC3-5">
      <title>Drugs in the news</title>
      <p>Given the lack of approved therapeutic options, the COVID-19 pandemic has heightened the interest in approved medicines that are suitable for drug repositioning. A number of them have been used off-label in COVID-19 patients, and are therefore of interest to the community at large. Assessment of evidence for COVID-19-related treatments are frequently updated by the American Society of Health-System Pharmacists, AHSP (<ext-link ext-link-type="uri" xlink:href="https://bit.ly/3mvXCQX">https://bit.ly/3mvXCQX</ext-link>). Reflecting heightened interest in COVID-19, the front-page of DrugCentral 2021 now includes a list of drugs that are ‘in the news’ (Figure <xref ref-type="fig" rid="F3">3</xref>). The current list includes favipiravir, which is not available in the US, but approved as Avigan in Japan and Russia and emergency approved in Italy (<xref rid="B48" ref-type="bibr">48</xref>) and remdesivir, which was granted emergency authorization in Japan and was FDA-approved as Veklury (<ext-link ext-link-type="uri" xlink:href="https://bit.ly/33zA8Su">https://bit.ly/33zA8Su</ext-link>), among other drugs.</p>
      <fig id="F3" orientation="portrait" position="float">
        <label>Figure 3.</label>
        <caption>
          <p>Front-page of the Drugcentral 2021 portal, featuring remdesivir in the chemical structure window.</p>
        </caption>
        <graphic xlink:href="gkaa997fig3"/>
      </fig>
    </sec>
  </sec>
  <sec id="SEC4">
    <title>SUMMARY AND FUTURE DIRECTIONS</title>
    <p>DrugCentral 2021 is up-to-date with drug marketing approvals and patent/exclusivity annotations up to 31 March 2020 and 23 June 2020, respectively. We incorporated ADMET-PK data and sex-based adverse events from FAERS, in addition to an anti-SARS-CoV-2 activities prediction server. At its core, DrugCentral continues to index {pharmaceutical formulation—drug—drug target—disease} association, although a significant number of additional attributes have been added to facilitate drug discovery and repositioning. We will continue to incorporate new drugs as soon as regulatory approvals are published. Drugs withdrawn due to other than safety reasons will be flagged in the OFM category, and all other drugs will be annually updated with respect to their marketing/patent/exclusivity status (<xref rid="B13" ref-type="bibr">13</xref>) in order to maintain easily accessible lists for drug repositioning. The FAERS interface will be streamlined to highlight sex differences in the drug safety profiles of existing drugs. Within the next six months, we plan to launch a chemical substructure and similarity search functionality. Last but not least, we have performed an extensive curation of veterinary drugs, which will be annotated in the next major DrugCentral release.</p>
  </sec>
  <sec id="SEC5">
    <title>DATA ACCESS</title>
    <sec id="SEC5-1">
      <title>Web interface</title>
      <p>The DrugCentral web interface has been updated since the 2018 release to integrate novel data types and functionalities. The ‘Drugs in the news’ section will be updated monthly, by monitoring drugs that are widely associated with current events.</p>
    </sec>
    <sec id="SEC5-2">
      <title>Download</title>
      <p>DrugCentral data can be downloaded in PostgreSQL format (full database dump available) for advanced data query, export and integration. User interaction with the local instance is facilitated through structured query language (SQL) examples as previously available, together with downloads of the chemical structures of the drugs in several formats (e.g. SDF, InChI and SMILES) and drugs bioactivity profiles in tabular format. The database is available via Docker container (<ext-link ext-link-type="uri" xlink:href="https://dockr.ly/35G46a6">https://dockr.ly/35G46a6</ext-link>), and public instance drugcentral:unmtid-dbs.net:5433. A Python API is also available (<ext-link ext-link-type="uri" xlink:href="https://bit.ly/2RAHRtV">https://bit.ly/2RAHRtV</ext-link>).</p>
    </sec>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sup1">
      <label>gkaa997_Supplemental_File</label>
      <media xlink:href="gkaa997_supplemental_file.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <sec id="SEC6">
    <title>SUPPLEMENTARY DATA</title>
    <p><ext-link ext-link-type="uri" xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkaa997#supplementary-data">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC7">
    <title>FUNDING</title>
    <p>National Institutes of Health (NIH) Common Fund [U24 CA224370 to S.A., C.G.B., J.H., T.B.W., R.C., L.H., A.B., J.J.Y., J.K., T.I.O.]; NIH National Cancer Institute (NCI) Cancer Center Support Grant for UNM [P30 CA118100 to C.G.B., T.I.O.]; NIH NCATS Clinical and Translational Science Center for UNM [UL1 TR001449 to T.I.O.]; Intramural Research Program, Division of Preclinical Innovation, NIH NCATS (to D.T.N.); National Science Foundation [NSF-PREM, DMR-1827745 to S.S.]. Funding for open access charge: NIH [CA224370].</p>
    <p><italic>Conflict of interest statement</italic>. T.I.O. has received honoraria or consulted for Abbott, AstraZeneca, Chiron, Genentech, Infinity Pharmaceuticals, Merz Pharmaceuticals, Merck Darmstadt, Mitsubishi Tanabe, Novartis, Ono Pharmaceuticals, Pfizer, Roche, Sanofi and Wyeth. He is on the Scientific Advisory Board of ChemDiv Inc. and InSilico Medicine.</p>
  </sec>
  <ref-list id="REF1">
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ursu</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Holmes</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Knockel</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Bologa</surname><given-names>C.G.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J.J.</given-names></name>, <name name-style="western"><surname>Mathias</surname><given-names>S.L.</given-names></name>, <name name-style="western"><surname>Nelson</surname><given-names>S.J.</given-names></name>, <name name-style="western"><surname>Oprea</surname><given-names>T.I.</given-names></name></person-group><article-title>DrugCentral: online drug compendium</article-title>. <source>Nucleic. Acids. Res.</source><year>2017</year>; <volume>45</volume>:<fpage>D932</fpage>–<lpage>D939</lpage>.<pub-id pub-id-type="pmid">27789690</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><collab>UniProtConsortium</collab><article-title>UniProt: a worldwide hub of protein knowledge</article-title>. <source>Nucleic. Acids. Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D506</fpage>–<lpage>D515</lpage>.<pub-id pub-id-type="pmid">30395287</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hastings</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Owen</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Dekker</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Ennis</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Kale</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Muthukrishnan</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Turner</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Swainston</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Mendes</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Steinbeck</surname><given-names>C.</given-names></name></person-group><article-title>ChEBI in 2016: Improved services and an expanding collection of metabolites</article-title>. <source>Nucleic. Acids. Res.</source><year>2016</year>; <volume>44</volume>:<fpage>D1214</fpage>–<lpage>D1219</lpage>.<pub-id pub-id-type="pmid">26467479</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Himmelstein</surname><given-names>D.S.</given-names></name>, <name name-style="western"><surname>Lizee</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Hessler</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Brueggeman</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>S.L.</given-names></name>, <name name-style="western"><surname>Hadley</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Green</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Khankhanian</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Baranzini</surname><given-names>S.E.</given-names></name></person-group><article-title>Systematic integration of biomedical knowledge prioritizes drugs for repurposing</article-title>. <source>Elife</source>. <year>2017</year>; <volume>6</volume>:<fpage>e26726</fpage>.<pub-id pub-id-type="pmid">28936969</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguirre-Plans</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Piñero</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Sanz</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Furlong</surname><given-names>L.I.</given-names></name>, <name name-style="western"><surname>Fernandez-Fuentes</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Oliva</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Guney</surname><given-names>E.</given-names></name></person-group><article-title>GUILDify v2.0: A tool to identify molecular networks underlying human diseases, their comorbidities and their druggable targets</article-title>. <source>J. Mol. Biol.</source><year>2019</year>; <volume>431</volume>:<fpage>2477</fpage>–<lpage>2484</lpage>.<pub-id pub-id-type="pmid">30851278</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chambers</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Davies</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Gaulton</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Hersey</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Velankar</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Petryszak</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Hastings</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Bellis</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>McGlinchey</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Overington</surname><given-names>J.P.</given-names></name></person-group><article-title>UniChem: a unified chemical structure cross-referencing and identifier tracking system</article-title>. <source>J. Cheminform.</source><year>2013</year>; <volume>5</volume>:<fpage>3</fpage>.<pub-id pub-id-type="pmid">23317286</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>S.P.H.</given-names></name>, <name name-style="western"><surname>Kelly</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Mathie</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Peters</surname><given-names>J.A.</given-names></name>, <name name-style="western"><surname>Veale</surname><given-names>E.L.</given-names></name>, <name name-style="western"><surname>Armstrong</surname><given-names>J.F.</given-names></name>, <name name-style="western"><surname>Faccenda</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Harding</surname><given-names>S.D.</given-names></name>, <name name-style="western"><surname>Pawson</surname><given-names>A.J.</given-names></name>, <name name-style="western"><surname>Sharman</surname><given-names>J.L.</given-names></name><etal>et al</etal>.</person-group><article-title>The concise guide to pharmacology 2019/20: Introduction and other protein targets</article-title>. <source>Br. J. Pharmacol.</source><year>2019</year>; <volume>176</volume>:<fpage>S1</fpage>–<lpage>S20</lpage>.<pub-id pub-id-type="pmid">31710719</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>A.S.</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>C.J.</given-names></name></person-group><article-title>A standard database for drug repositioning</article-title>. <source>Scientific Data</source>. <year>2017</year>; <volume>4</volume>:<fpage>170029</fpage>.<pub-id pub-id-type="pmid">28291243</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayers</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>T.S.</given-names></name>, <name name-style="western"><surname>Queralt-Rosinach</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>A.I.</given-names></name></person-group><article-title>Time-resolved evaluation of compound repositioning predictions on a text-mined knowledge network</article-title>. <source>BMC Bioinformatics</source>. <year>2019</year>; <volume>20</volume>:<fpage>653</fpage>.<pub-id pub-id-type="pmid">31829175</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Taboureau</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Audouze</surname><given-names>K.</given-names></name></person-group><article-title>Development of an adverse drug event network to predict drug toxicity</article-title>. <source>Current Research in Toxicology</source>. <year>2020</year>; <volume>1</volume>:<fpage>48</fpage>–<lpage>55</lpage>.</mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ursu</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Holmes</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Bologa</surname><given-names>C.G.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J.J.</given-names></name>, <name name-style="western"><surname>Mathias</surname><given-names>S.L.</given-names></name>, <name name-style="western"><surname>Stathias</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Nguyen</surname><given-names>D.-T.</given-names></name>, <name name-style="western"><surname>Schürer</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Oprea</surname><given-names>T.</given-names></name></person-group><article-title>DrugCentral 2018: an update</article-title>. <source>Nucleic. Acids. Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D963</fpage>–<lpage>D970</lpage>.<pub-id pub-id-type="pmid">30371892</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levin</surname><given-names>J.M.</given-names></name>, <name name-style="western"><surname>Oprea</surname><given-names>T.I.</given-names></name>, <name name-style="western"><surname>Davidovich</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Clozel</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Overington</surname><given-names>J.P.</given-names></name>, <name name-style="western"><surname>Vanhaelen</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Cantor</surname><given-names>C.R.</given-names></name>, <name name-style="western"><surname>Bischof</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Zhavoronkov</surname><given-names>A.</given-names></name></person-group><article-title>Artificial intelligence, drug repurposing and peer review</article-title>. <source>Nat. Biotechnol.</source><year>2020</year>; <volume>38</volume>:<fpage>1127</fpage>–<lpage>1131</lpage>.<pub-id pub-id-type="pmid">32929264</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avram</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Curpan</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Halip</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Bora</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Oprea</surname><given-names>T.I.</given-names></name></person-group><article-title>Off-patent drug repositioning</article-title>. <source>J. Chem. Inf. Model.</source><year>2020</year>; <comment>doi:10.1021/acs.jcim.0c00826</comment>.</mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>KC</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Bocci</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Verma</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Hassan</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Holmes</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Sirimulla</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Oprea</surname><given-names>T.I.</given-names></name></person-group><article-title>REDIAL-2020: A suite of machine learning models to estimate Anti-SARS-CoV-2 activities</article-title>. <year>2020</year>; <comment>ChemRxiv doi:</comment><comment>16 September 2020, preprint: not peer reviewed</comment><pub-id pub-id-type="doi">10.26434/chemrxiv.12915779</pub-id>.</mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avram</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Halip</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Curpan</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Oprea</surname><given-names>T.I.</given-names></name></person-group><article-title>Novel drug targets in 2019</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2020</year>; <volume>19</volume>:<fpage>300</fpage>.<pub-id pub-id-type="pmid">32273590</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tambuyzer</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Vandendriessche</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Austin</surname><given-names>C.P.</given-names></name>, <name name-style="western"><surname>Brooks</surname><given-names>P.J.</given-names></name>, <name name-style="western"><surname>Larsson</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Miller Needleman</surname><given-names>K.I.</given-names></name>, <name name-style="western"><surname>Valentine</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Davies</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Groft</surname><given-names>S.C.</given-names></name>, <name name-style="western"><surname>Preti</surname><given-names>R.</given-names></name><etal>et al</etal>.</person-group><article-title>Therapies for rare diseases: therapeutic modalities, progress and challenges ahead</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2020</year>; <volume>19</volume>:<fpage>93</fpage>–<lpage>111</lpage>.<pub-id pub-id-type="pmid">31836861</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendez</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Gaulton</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Bento</surname><given-names>A.P.</given-names></name>, <name name-style="western"><surname>Chambers</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>De Veij</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Félix</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Magariños</surname><given-names>M.P.</given-names></name>, <name name-style="western"><surname>Mosquera</surname><given-names>J.F.</given-names></name>, <name name-style="western"><surname>Mutowo</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Nowotka</surname><given-names>M.</given-names></name><etal>et al</etal>.</person-group><article-title>ChEMBL: towards direct deposition of bioassay data</article-title>. <source>Nucleic. Acids. Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D930</fpage>–<lpage>D940</lpage>.<pub-id pub-id-type="pmid">30398643</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanehisa</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Sato</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Furumichi</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Morishima</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Tanabe</surname><given-names>M.</given-names></name></person-group><article-title>New approach for understanding genome variations in KEGG</article-title>. <source>Nucleic. Acids. Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D590</fpage>–<lpage>D595</lpage>.<pub-id pub-id-type="pmid">30321428</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oprea</surname><given-names>T.I.</given-names></name>, <name name-style="western"><surname>Bologa</surname><given-names>C.G.</given-names></name>, <name name-style="western"><surname>Brunak</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Campbell</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Gan</surname><given-names>G.N.</given-names></name>, <name name-style="western"><surname>Gaulton</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Gomez</surname><given-names>S.M.</given-names></name>, <name name-style="western"><surname>Guha</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Hersey</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Holmes</surname><given-names>J.</given-names></name><etal>et al</etal>.</person-group><article-title>Unexplored therapeutic opportunities in the human genome</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2018</year>; <volume>17</volume>:<fpage>317</fpage>–<lpage>332</lpage>.<pub-id pub-id-type="pmid">29472638</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Ursu</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Gaulton</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Bento</surname><given-names>A.P.</given-names></name>, <name name-style="western"><surname>Donadi</surname><given-names>R.S.</given-names></name>, <name name-style="western"><surname>Bologa</surname><given-names>C.G.</given-names></name>, <name name-style="western"><surname>Karlsson</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Al-Lazikani</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Hersey</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Oprea</surname><given-names>T.I.</given-names></name><etal>et al</etal>.</person-group><article-title>A comprehensive map of molecular drug targets</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2017</year>; <volume>16</volume>:<fpage>19</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">27910877</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ursu</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Glick</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Oprea</surname><given-names>T.</given-names></name></person-group><article-title>Novel drug targets in 2018</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2019</year>; <volume>18</volume>:<fpage>328</fpage>.</mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashburner</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Ball</surname><given-names>C.A.</given-names></name>, <name name-style="western"><surname>Blake</surname><given-names>J.A.</given-names></name>, <name name-style="western"><surname>Botstein</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Butler</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Cherry</surname><given-names>J.M.</given-names></name>, <name name-style="western"><surname>Davis</surname><given-names>A.P.</given-names></name>, <name name-style="western"><surname>Dolinski</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Dwight</surname><given-names>S.S.</given-names></name>, <name name-style="western"><surname>Eppig</surname><given-names>J.T.</given-names></name><etal>et al</etal>.</person-group><article-title>Gene ontology: tool for the unification of biology. The Gene Ontology Consortium</article-title>. <source>Nat. Genet.</source><year>2000</year>; <volume>25</volume>:<fpage>25</fpage>–<lpage>29</lpage>.<pub-id pub-id-type="pmid">10802651</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pafilis</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Frankild</surname><given-names>S.P.</given-names></name>, <name name-style="western"><surname>Fanini</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Faulwetter</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Pavloudi</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Vasileiadou</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Arvanitidis</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Jensen</surname><given-names>L.J.</given-names></name></person-group><article-title>The SPECIES and ORGANISMS resources for fast and accurate identification of taxonomic names in text</article-title>. <source>PLoS One</source>. <year>2013</year>; <volume>8</volume>:<fpage>e65390</fpage>.<pub-id pub-id-type="pmid">23823062</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Björling</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Uhlén</surname><given-names>M.</given-names></name></person-group><article-title>Antibodypedia, a portal for sharing antibody and antigen validation data</article-title>. <source>Mol. Cell. Proteomics</source>. <year>2008</year>; <volume>7</volume>:<fpage>2028</fpage>–<lpage>2037</lpage>.<pub-id pub-id-type="pmid">18667413</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>D.-T.</given-names></name>, <name name-style="western"><surname>Mathias</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Bologa</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Brunak</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Fernandez</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Gaulton</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Hersey</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Holmes</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Jensen</surname><given-names>L.J.</given-names></name>, <name name-style="western"><surname>Karlsson</surname><given-names>A.</given-names></name><etal>et al</etal>.</person-group><article-title>Pharos: Collating protein information to shed light on the druggable genome</article-title>. <source>Nucleic. Acids. Res.</source><year>2017</year>; <volume>45</volume>:<fpage>D995</fpage>–<lpage>D1002</lpage>.<pub-id pub-id-type="pmid">27903890</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheils</surname><given-names>T.K.</given-names></name>, <name name-style="western"><surname>Mathias</surname><given-names>S.L.</given-names></name>, <name name-style="western"><surname>Kelleher</surname><given-names>K.J.</given-names></name>, <name name-style="western"><surname>Siramshetty</surname><given-names>V.B.</given-names></name>, <name name-style="western"><surname>Nguyen</surname><given-names>D.-T.</given-names></name>, <name name-style="western"><surname>Bologa</surname><given-names>C.G.</given-names></name>, <name name-style="western"><surname>Jensen</surname><given-names>L.J.</given-names></name>, <name name-style="western"><surname>Vidović</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Koleti</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Schürer</surname><given-names>S.C.</given-names></name><etal>et al</etal>.</person-group><article-title>TCRD and Pharos 2021: Mining the human proteome for disease biology</article-title>. <source>Nucleic. Acids. Res.</source><year>2021</year>; <comment>https://doi.org/10.1093/nar/gkaa993</comment>.</mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>S.J.</given-names></name></person-group><article-title>Medical terminologies that work: The example of MeSH</article-title>. <source>2009 10th International Symposium on Pervasive Systems, Algorithms, and Networks</source>. <year>2009</year>; <fpage>380</fpage>–<lpage>384</lpage>.</mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oprea</surname><given-names>T.I.</given-names></name>, <name name-style="western"><surname>Overington</surname><given-names>J.P.</given-names></name></person-group><article-title>Computational and practical aspects of drug repositioning</article-title>. <source>Assay Drug Dev. Technol.</source><year>2015</year>; <volume>13</volume>:<fpage>299</fpage>–<lpage>306</lpage>.<pub-id pub-id-type="pmid">26241209</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>M.T.</given-names></name>, <name name-style="western"><surname>Sedykh</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Chakravarti</surname><given-names>S.K.</given-names></name>, <name name-style="western"><surname>Saiakhov</surname><given-names>R.D.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name></person-group><article-title>Critical evaluation of human oral bioavailability for pharmaceutical drugs by using various cheminformatics approaches</article-title>. <source>Pharm. Res.</source><year>2014</year>; <volume>31</volume>:<fpage>1002</fpage>–<lpage>1014</lpage>.<pub-id pub-id-type="pmid">24306326</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lombardo</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Berellini</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Obach</surname><given-names>R.S.</given-names></name></person-group><article-title>Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 1352 drug compounds</article-title>. <source>Drug Metab. Dispos.</source><year>2018</year>; <volume>46</volume>:<fpage>1466</fpage>–<lpage>1477</lpage>.<pub-id pub-id-type="pmid">30115648</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benet</surname><given-names>L.Z.</given-names></name>, <name name-style="western"><surname>Broccatelli</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Oprea</surname><given-names>T.I.</given-names></name></person-group><article-title>BDDCS applied to over 900 drugs</article-title>. <source>AAPS J.</source><year>2011</year>; <volume>13</volume>:<fpage>519</fpage>–<lpage>547</lpage>.<pub-id pub-id-type="pmid">21818695</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hosey</surname><given-names>C.M.</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Benet</surname><given-names>L.Z.</given-names></name></person-group><article-title>BDDCS predictions, Self-Correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs</article-title>. <source>AAPS J.</source><year>2016</year>; <volume>18</volume>:<fpage>251</fpage>–<lpage>260</lpage>.<pub-id pub-id-type="pmid">26589308</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Contrera</surname><given-names>J.F.</given-names></name>, <name name-style="western"><surname>Matthews</surname><given-names>E.J.</given-names></name>, <name name-style="western"><surname>Kruhlak</surname><given-names>N.L.</given-names></name>, <name name-style="western"><surname>Benz</surname><given-names>R.D.</given-names></name></person-group><article-title>Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose</article-title>. <source>Regul. Toxicol. Pharmacol.</source><year>2004</year>; <volume>40</volume>:<fpage>185</fpage>–<lpage>206</lpage>.<pub-id pub-id-type="pmid">15546675</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shugarts</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Benet</surname><given-names>L.Z.</given-names></name></person-group><article-title>The role of transporters in the pharmacokinetics of orally administered drugs</article-title>. <source>Pharm. Res.</source><year>2009</year>; <volume>26</volume>:<fpage>2039</fpage>–<lpage>2054</lpage>.<pub-id pub-id-type="pmid">19568696</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broccatelli</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Larregieu</surname><given-names>C.A.</given-names></name>, <name name-style="western"><surname>Cruciani</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Oprea</surname><given-names>T.I.</given-names></name>, <name name-style="western"><surname>Benet</surname><given-names>L.Z.</given-names></name></person-group><article-title>Improving the prediction of the brain disposition for orally administered drugs using BDDCS</article-title>. <source>Adv. Drug Deliv. Rev.</source><year>2012</year>; <volume>64</volume>:<fpage>95</fpage>–<lpage>109</lpage>.<pub-id pub-id-type="pmid">22261306</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bocci</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Benet</surname><given-names>L.Z.</given-names></name>, <name name-style="western"><surname>Oprea</surname><given-names>T.I.</given-names></name></person-group><article-title>Can BDDCS illuminate targets in drug design?</article-title>. <source>Drug Discov. Today</source>. <year>2019</year>; <volume>24</volume>:<fpage>2299</fpage>–<lpage>2306</lpage>.<pub-id pub-id-type="pmid">31585170</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashar</surname><given-names>B.H.</given-names></name></person-group><article-title>In search of the 70-kg man</article-title>. <source>Med. Clin. North Am.</source><year>2018</year>; <volume>102</volume>:<fpage>xv</fpage>–<lpage>xvi</lpage>.</mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zalkikar</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Tiwari</surname><given-names>R.C.</given-names></name></person-group><article-title>A likelihood ratio test based method for signal detection with application to FDA’s drug safety data</article-title>. <source>J. Am. Stat. Assoc.</source><year>2011</year>; <volume>106</volume>:<fpage>1230</fpage>–<lpage>1241</lpage>.</mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name></person-group><article-title>Systematic analysis of adverse event reports for sex differences in adverse drug events</article-title>. <source>Sci. Rep.</source><year>2016</year>; <volume>6</volume>:<fpage>24955</fpage>.<pub-id pub-id-type="pmid">27102014</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Vries</surname><given-names>S.T.</given-names></name>, <name name-style="western"><surname>Denig</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Ekhart</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Burgers</surname><given-names>J.S.</given-names></name>, <name name-style="western"><surname>Kleefstra</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Mol</surname><given-names>P.G.M.</given-names></name>, <name name-style="western"><surname>van Puijenbroek</surname><given-names>E.P.</given-names></name></person-group><article-title>Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study</article-title>. <source>Br. J. Clin. Pharmacol.</source><year>2019</year>; <volume>85</volume>:<fpage>1507</fpage>–<lpage>1515</lpage>.<pub-id pub-id-type="pmid">30941789</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>A.M.</given-names></name>, <name name-style="western"><surname>Tingen</surname><given-names>C.M.</given-names></name>, <name name-style="western"><surname>Woodruff</surname><given-names>T.K.</given-names></name></person-group><article-title>Sex bias in trials and treatment must end</article-title>. <source>Nature</source>. <year>2010</year>; <volume>465</volume>:<fpage>688</fpage>–<lpage>689</lpage>.<pub-id pub-id-type="pmid">20535184</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oprea</surname><given-names>T.I.</given-names></name></person-group><article-title>Exploring the dark genome: implications for precision medicine</article-title>. <source>Mamm. Genome</source>. <year>2019</year>; <volume>30</volume>:<fpage>192</fpage>–<lpage>200</lpage>.<pub-id pub-id-type="pmid">31270560</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Brimacombe</surname><given-names>K.R.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Eastman</surname><given-names>R.T.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Backus</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Baljinnyam</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>C.Z.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Eicher</surname><given-names>T.</given-names></name><etal>et al</etal>.</person-group><article-title>An OpenData portal to share COVID-19 drug repurposing data in real time</article-title>. <year>2020</year>; <comment>bioRxiv doi:</comment><comment>05 June 2020, preprint: not peer reviewed</comment><pub-id pub-id-type="doi">10.1101/2020.06.04.135046</pub-id>.</mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C.Z.</given-names></name>, <name name-style="western"><surname>Shinn</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Itkin</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Eastman</surname><given-names>R.T.</given-names></name>, <name name-style="western"><surname>Bostwick</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Rasmussen</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>K.M.</given-names></name><etal>et al</etal>.</person-group><article-title>Drug repurposing screen for compounds inhibiting the cytopathic effect of SARS-CoV-2</article-title>. <year>2020</year>; <comment>bioRxiv doi:</comment><comment>18 August 2020, preprint: not peer reviewed</comment><pub-id pub-id-type="doi">10.1101/2020.08.18.255877</pub-id>.</mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Hanson</surname><given-names>Q.M.</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>K.M.</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Itkin</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Eastman</surname><given-names>R.T.</given-names></name>, <name name-style="western"><surname>Shinn</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Hall</surname><given-names>M.D.</given-names></name></person-group><article-title>Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay</article-title>. <year>2020</year>; <comment>bioRxiv doi:</comment><comment>16 June 2020, preprint: not peer reviewed</comment><pub-id pub-id-type="doi">10.1101/2020.06.16.154708</pub-id>.</mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>C.Z.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Shinn</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Klumpp-Thomas</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Michael</surname><given-names>S.G.</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>W.</given-names></name></person-group><article-title>Identification of SARS-CoV-2 3CL protease inhibitors by a quantitative high-throughput screening</article-title>. <source>ACS Pharmacol. Transl. Sci.</source><year>2020</year>; <volume>3</volume>:<fpage>1008</fpage>–<lpage>1016</lpage>.<pub-id pub-id-type="pmid">33062953</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedregosa</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Varoquaux</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Gramfort</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Michel</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Thirion</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Grisel</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Blondel</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Prettenhofer</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Weiss</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Dubourg</surname><given-names>V.</given-names></name><etal>et al</etal>.</person-group><article-title>Scikit-learn: Machine learning in Python</article-title>. <source>J. Mach. Learn Res.</source><year>2011</year>; <volume>12</volume>:<fpage>2825</fpage>–<lpage>2830</lpage>.</mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>U.</given-names></name>, <name name-style="western"><surname>Raju</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Udwadia</surname><given-names>Z.F.</given-names></name></person-group><article-title>Favipiravir: A new and emerging antiviral option in COVID-19</article-title>. <source>Armed Forces Med. J. India</source>. <year>2020</year>; <comment>doi:10.1016/j.mjafi.2020.08.004</comment>.</mixed-citation>
    </ref>
  </ref-list>
</back>
